TL;DR: The cannabis sector enters the week of July 28 with Tilray Brands (TLRY) reporting Q4 FY2026 earnings on Monday as the first major cannabis company catalyst of the summer reporting season. The AdvisorShares MSOS ETF recovered from $4.26 to $4.35 in after-hours trading on July 24, suggesting cautious institutional repositioning ahead of the earnings window. With Green Thumb Industries (GTBIF) reporting August 4 and Curaleaf (CURLF) on August 5, investors should track the sector’s evolving picture on the cannabis stock tracker throughout the sequence.
Market Analysis
The week of July 28 through August 1 opens one of the most concentrated catalyst windows in the cannabis sector’s 2026 calendar. Tilray Brands (TLRY), the Nasdaq-listed cannabis and beverage hybrid, reports Q4 FY2026 earnings on July 28 — after the stock closed at $3.88 on Friday, within a few cents of its 52-week low of $3.80. The after-hours session on July 24 showed a partial recovery to $3.91, though TLRY remains well below the 52-week high of $23.20, reflecting a year defined by integration costs, impairment charges, and investor skepticism about the diversified business model’s long-term coherence.
Tilray’s Q3 FY2026 delivered $206.73 million in revenue, with the company maintaining $425.66 million in cash — a balance sheet resource that provides runway while the strategic direction clarifies. The current valuation at a price-to-sales ratio of 0.48 prices the stock at less than half its annual revenue, a multiple that reflects operational uncertainty rather than the full asset picture. TD Cowen maintained a Buy rating in mid-July while lowering the price target from $7.00 to $5.00, a revision that acknowledges near-term earnings pressure while retaining a constructive longer-term view on the company’s international cannabis and beverage platform.
For the MSOS ETF, the week-ahead setup reflects the sector’s binary positioning dynamic. With net assets of approximately $1.05 billion, MSOS’s top two holdings — Curaleaf (CURA.TO at 12.18% of assets) and Trulieve Cannabis Corp. at 9.45% — represent meaningful concentration in operators whose own reporting falls in early August. The fund’s after-hours recovery from $4.26 to $4.35 on July 24 may reflect institutional positioning ahead of earnings-season volatility, though the YTD decline of 9.75% against a one-year gain of approximately 50% illustrates the sector’s ongoing struggle to establish a durable baseline.
Green Thumb Industries (GTBIF), the sector’s most consistently profitable domestic MSO with a $1.2 billion TTM revenue base and a 10.14% profit margin, reports on August 4. Curaleaf, the sector’s largest operator by market capitalization at $2.51 billion and 1-year return of 158.47%, follows on August 5. Together, these three reports spanning July 28 through August 5 will define the institutional narrative for cannabis equities through the remainder of summer.
Regulatory and Market Context
The earnings calendar arrives against the most consequential regulatory backdrop the U.S. cannabis sector has faced in a generation. The DEA’s proposed rescheduling of cannabis from Schedule I to Schedule III has progressed into its administrative evidence phase, with the administrative law process establishing the evidentiary record that will ultimately inform the final rule. For operators reporting Q2 results in August, management commentary on 280E tax planning — specifically whether the rescheduling timeline has shifted balance sheet provisioning assumptions — will be among the most closely watched qualitative data points by institutional analysts.
SAFE Banking remains embedded in the sector’s cost of capital. Without explicit federal banking access, cannabis operators continue to absorb elevated borrowing costs and operational friction that compress free cash flow relative to comparably sized consumer goods peers. A Schedule III final rule, while not automatically triggering SAFE Banking reform, could accelerate Congressional action on financial services provisions — a linkage that analysts and operators have increasingly emphasized in recent earnings calls.
Tilray’s international cannabis segment, serving Germany, the United Kingdom, Australia, and other regulated markets, provides revenue diversification that domestic MSOs largely lack. Monday’s report will draw focus on whether Germany’s partial legalization framework has generated incremental international revenue and whether the beverage alcohol segment has achieved stabilization following several quarters of integration complexity. Both questions carry implications for how the market values Tilray’s hybrid business model through the second half of 2026.
Conclusion
The cannabis sector’s most earnings-dense stretch of the summer begins Monday with Tilray and extends through the first week of August. Investors monitoring the space should watch MSOS’s response to the TLRY print as an early signal for how institutional flows are positioned ahead of the domestic MSO reporting sequence — with Green Thumb on August 4 and Curaleaf on August 5 representing the U.S. operating picture that will ultimately drive the sector’s next directional move. The combination of an active DEA rulemaking process and a compressed earnings calendar makes the next ten trading days among the most information-dense of the year for cannabis market participants.